290 related articles for article (PubMed ID: 31261170)
21. A clinically applicable molecular-based classification for endometrial cancers.
Talhouk A; McConechy MK; Leung S; Li-Chang HH; Kwon JS; Melnyk N; Yang W; Senz J; Boyd N; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Br J Cancer; 2015 Jul; 113(2):299-310. PubMed ID: 26172027
[TBL] [Abstract][Full Text] [Related]
22. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
23. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
[TBL] [Abstract][Full Text] [Related]
25. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
26. The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility.
Hussein YR; Broaddus R; Weigelt B; Levine DA; Soslow RA
Int J Gynecol Pathol; 2016 Jan; 35(1):16-24. PubMed ID: 26166718
[TBL] [Abstract][Full Text] [Related]
27. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
[TBL] [Abstract][Full Text] [Related]
28. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
[TBL] [Abstract][Full Text] [Related]
29. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
30. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
Wu Q; Zhang N; Xie X
BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
[TBL] [Abstract][Full Text] [Related]
32. Primum non nocere: Are we ready for POLE testing in endometrial cancer?
Cosgrove CM; Cohn DE; Goodfellow PJ
Gynecol Oncol; 2017 Nov; 147(2):240-242. PubMed ID: 28947175
[No Abstract] [Full Text] [Related]
33. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.
Travaglino A; Raffone A; Gencarelli A; Mollo A; Guida M; Insabato L; Santoro A; Zannoni GF; Zullo F
Pathol Oncol Res; 2020 Oct; 26(4):2067-2073. PubMed ID: 32472441
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
Veneris JT; Lee EK; Goebel EA; Nucci MR; Lindeman N; Horowitz NS; Lee L; Raut CP; Crotzer D; Matulonis U; Konstantinopoulos PA; Campos S
Gynecol Oncol; 2019 Jun; 153(3):471-478. PubMed ID: 30935717
[TBL] [Abstract][Full Text] [Related]
35. Histopathological characterization of ProMisE molecular groups of endometrial cancer.
Raffone A; Travaglino A; Mascolo M; Carotenuto C; Guida M; Mollo A; Insabato L; Zullo F
Gynecol Oncol; 2020 Apr; 157(1):252-259. PubMed ID: 31932106
[TBL] [Abstract][Full Text] [Related]
36. [Endometrial carcinomas in 2021: What to say and what to do?].
Just PA; Genestie C
Ann Pathol; 2022 Mar; 42(2):104-112. PubMed ID: 34340872
[TBL] [Abstract][Full Text] [Related]
37. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
[TBL] [Abstract][Full Text] [Related]
38. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.
Casey L; Singh N
Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350
[TBL] [Abstract][Full Text] [Related]
39. Molecular insights into the classification of high-grade endometrial carcinoma.
Hussein YR; Soslow RA
Pathology; 2018 Feb; 50(2):151-161. PubMed ID: 29246451
[TBL] [Abstract][Full Text] [Related]
40. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
